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The number of chemicals identified as endocrine disruptors continues to rise, and, yet, many assays intended
to prioritize them for further action cannot gauge their impact on cells. Stossi and colleagues present new
high-throughput screening methods that inform estrogen receptor biology, leading to questions about
‘‘safe alternatives’’ for one compound, bisphenol A.The study of chemicals that interfere with
endocrine signaling, termed endocrine
disruptors, has advanced tremendously
since the term was first coined in the
1990s (Zoeller et al., 2012). Today, more
than 1,000 chemicals have been identified
as putative endocrine disruptors based
largely on their ability to bind to estrogen
receptor (ER) a, ERb, androgen receptor,
and thyroid receptor. The mechanisms
involved in endocrine disruption are very
often complex and involve hormone re-
ceptor agonists and antagonists, chemi-
cals that induce the expression of
enzymes responsible for hormone syn-
thesis and disrupt the transport and
release of hormones, among other
effects. In this issue of Chemistry &
Biology, Stossi et al. (2014) report a suite
of high-throughput assays aimed at un-
covering how these chemicals impact
cellular physiology.
In 1996, laws passed by the United
States Congress required the Environ-
mental Protection Agency (EPA) to screen
pesticides for endocrine disrupting prop-
erties. In response, the EPA developed a
two-tiered screening program. Tier 1
assays include in vitro and in vivo screens
to assess the potential for compounds to
interfere with estrogen and androgen
signaling, whereas tier 2 involves more
complicated and long-term assessments
of chemical toxicity. Compounds are
only tested in tier 2 if the evidence from
tier 1 is sufficient to conclude that the
compound might be an endocrine dis-
ruptor. Yet, numerous criticisms of the
tier 1 assays have been raised, centered
around the use of outdated and insensi-
tive assays (Myers et al., 2009; Zoeller
et al., 2012). One example is the uterotro-phic assay, an in vivo rodent screening
method developed in the 1930s that
uses the weight of the uterus to assess
whether a compound mimics the actions
of estrogen. This assay, while generating
reproducible results, has been shown to
be insensitive to compounds with estro-
genic properties that are readily revealed
in more state-of-the-art toxicity screens.
In an effort to modernize the tools used
to identify endocrine disruptors, in 2007,
the EPA launched ToxCast, a series of
more than 800 high-throughput in vitro
screening assays to be used to prioritize
chemicals for further in vivo testing, which
would also reduce the number of labora-
tory animal toxicity tests performed
(see details at http://www.epa.gov/ncct/
toxcast/). Already, ToxCast has been
used to assess the potential endocrine
disrupting properties of more than 300
chemicals (Reif et al., 2010). Yet, the
high-throughput assays included in
ToxCast often neglect important end-
points such as the physiological effects
of test chemicals on gene or protein
targets.
In this issue of Chemistry & Biology,
Stossi et al. (2014) have developed new
high-throughput microscopy-based as-
says that examine several aspects of ER
biology to provide additional mechanistic
insights into the endocrine disrupting
properties of environmental chemicals.
The new assays use multi-parametric
approaches to examine the effects of
putative endocrine disruptors on DNA-
and protein-based interactions, coactiva-
tor recruitment, chromatin remodeling,
and gene transcription. The assays have
several key aspects, including the unique
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nistic assays available in ToxCast.
As a case in point, Stossi et al. (2014)
examined how the well-studied endocrine
disruptor, bisphenol A (BPA), affects ER
biology. BPA is widely acknowledged to
have numerous endocrine disrupting
properties via mechanisms that include
binding to ERa, ERb, membrane ER,
GPR30, estrogen related receptor g,
androgen receptor, thyroid hormone re-
ceptor, and others (Vandenberg et al.,
2013). In the ToxCast screening of more
than 300 priority chemicals, BPA was
given the third highest toxicological prior-
ity score based on its ability to interact
with a large number of receptors and
signaling pathways (Reif et al., 2010).
Furthermore, several hundred in vitro,
laboratory animal and human epidemi-
ology studies have revealed effects of
low doses of BPA on a wide range of
health endpoints and have characterized
human exposures as widespread (Van-
denberg et al., 2013).
Because of public concerns with BPA
safety, numerous ‘‘BPA-free’’ products
have appeared on store shelves, often
marketed as ‘‘safer alternatives’’. Yet,
recent investigations have revealed that
many of these products contain poorly
studied BPA analogs including bisphenol
S and bisphenol F. Although studies are
limited at this point, there is evidence
that some of these compounds have
endocrine disrupting properties similar to
those of BPA (Kitamura et al., 2005;
Molina-Molina et al., 2013), and human
exposures may be as widespread as ex-
posures to BPA (Liao et al., 2012). Look-
ing at 18 of these compounds, Stossi
et al. (2014) find that many have a higherª2014 Elsevier Ltd All rights reserved 705
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Previewsaffinity for ERb than ERa and act as ERb
antagonists. These in vitro assays repre-
sent a start, and additional insights from
in vivo testing are needed to assess the
potential physiological effects of these
analogs.
From the perspective of molecular
biology and endocrinology, the new
assays developed by Stossi and col-
leagues will continue to advance our
understanding of the cellular and subcel-
lular mechanisms by which endocrine
disruptors alter estrogen signaling path-
ways. Yet, if the challenge of high-
throughput screening assays is to have
predictive value for human toxicity, these
techniques must also be considered in
the context of public health. One major
question continues to be raised: how
can the data from ToxCast be used to
regulate chemicals, if at all? Unfortu-
nately, the ToxCast study in which BPA
was given a high priority score (Reif
et al., 2010) has had limited, if any, influ-
ence on safety decisions regarding use
of this chemical.
ToxCast data are intended to aid prior-
itization of compounds for additional
testing; however, the use of compara-
tively insensitive assays to evaluate the706 Chemistry & Biology 21, June 19, 2014 ªsafety of BPA and other endocrine disrup-
tors has hindered progress toward mean-
ingful regulatory actions (Myers et al.,
2009; Zoeller et al., 2012). The emerging
concern is how BPA is being replaced in
many consumer products with poorly-
studied related compounds that appear
to have similar endocrine disrupting prop-
erties (Rosenmai et al., 2014). Such
‘‘regrettable replacements’’ should be
avoided, and a new standard in high-
throughput screening assays like those
presented by Stossi et al. (2014), together
with other state-of-the-art tools devel-
oped in the study of endocrine disruptors,
should be used long before these prod-
ucts reach the market (Schug et al.,
2013). Perhaps such data, raising con-
cerns about BPA analogs, will help
stimulate the development of nontoxic
chemicals for the future.
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